Welcome to our dedicated page for Indaptus Therapeutics SEC filings (Ticker: INDP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Indaptus Therapeutics filings document a clinical-stage biotechnology issuer developing Decoy20 and related immunotherapy programs for cancer and viral infections. The company’s regulatory record includes material-event reports, proxy statements, capital-structure disclosures, and governance filings tied to its Nasdaq-listed common stock.
Key filing subjects include convertible preferred stock, warrants, warrant repricing agreements, voting agreements, unregistered securities, shareholder meeting proposals, and changes in control. The filings also cover board and officer appointments or resignations, compensatory arrangements, operating and financial results, and material agreements that affect the company’s financing, governance, and public-company structure.
Indaptus Therapeutics, Inc. reported several leadership changes. Effective June 5, 2026, directors David E. Lazar and Avraham Ben-Tzvi resigned from all positions on the Board of Directors, including all committee roles. Effective June 1, 2026, Walt A. Linscott, Esq. resigned as Chief Operating Officer.
Linscott entered into a consulting agreement dated June 1, 2026 and will continue serving the company as a consultant in a strategic advisory role. The company stated that the resignations of Lazar, Ben-Tzvi, and Linscott were not the result of any disagreement with Indaptus on operations, policies, or practices.
Indaptus Therapeutics reported a Q1 2026 net loss of $2.54 million, improved from $4.53 million a year earlier, mainly because research and development spending fell to $0.49 million from $2.81 million as clinical activity was wound down. General and administrative expenses were stable at $1.67 million.
Cash and cash equivalents dropped to $1.50 million at March 31, 2026, after using $7.01 million in operating cash during the quarter. The company expects existing cash to fund operations only through the second quarter of 2026 and states there is substantial doubt about its ability to continue as a going concern.
All outstanding Series AA and Series AAA preferred shares issued in late 2025 converted into 111,000,000 common shares, bringing total shares outstanding to 113,242,324 at March 31, 2026. Indaptus has discontinued enrollment in its clinical studies and is evaluating strategic options for a post-investment transaction while keeping its immunotherapy platform as a potential asset.
Indaptus Therapeutics reported a first quarter 2026 net loss of about $2.5 million, improved from roughly $4.5 million a year earlier, as research and development spending declined sharply. R&D expenses fell to about $0.5 million from approximately $2.8 million, mainly from lower Phase 1 clinical costs and reduced payroll.
General and administrative expenses were about $1.7 million, slightly below the prior year. Cash and cash equivalents dropped to roughly $1.5 million as of March 31, 2026 from about $8.5 million at year-end 2025, with around $7.0 million used in operating activities in the quarter. The company states it will need to raise additional capital to support its business objectives and is evaluating financing alternatives and strategic options alongside a broader review of its development programs and Decoy platform.
Indaptus Therapeutics, Inc. received an ownership update from several large investors who amended their beneficial holdings and clarified their relationship. As of March 31, 2026, Yun Yao reports beneficial ownership of 41,991,000 shares of common stock, or 37.1% of the company. Sino Lion Ventures Limited and its controlling person, Chenhao Xu, each report 38,895,000 shares, representing 34.3% of the common stock. Junyi Dai and Ting Yang each report 11,250,000 shares, or 9.9%, while Lina Deng reports 5,550,000 shares, or 4.9%. All shares were issued upon conversion of Series AA and Series AAA Preferred Stock under a Securities Purchase Agreement that closed on March 23, 2026. The amendment states that the reporting persons have disbanded any group that may have existed under that agreement and will no longer act as a group, and it serves as an exit filing for Lina Deng, who fell below five percent ownership due to an increase in shares outstanding to 113,242,324.
Indaptus Therapeutics, Inc. filed an amended current report to update a director’s legal name to Johnny Fox Arrowsmith, previously disclosed as Yí Zhang. The amendment also restates recent board changes.
On April 17, 2026, the board appointed Tim Ruan and Dr. Johnny Fox Arrowsmith as independent directors, effective April 22, 2026. Both entered into independent director and indemnification agreements. Each will receive an annual cash retainer of $30,000, payable quarterly, plus reimbursement of reasonable expenses. The board determined both are independent under Nasdaq listing standards.
The board is divided into three classes. Mr. Ruan and Dr. Arrowsmith were appointed as Class II directors with terms expiring at the 2026 annual stockholders’ meeting. Junyi Dai and Qinglai Lu serve as Class III directors with terms expiring at the 2027 annual meeting.
Mr. Ruan was named to the audit committee and qualifies as an “audit committee financial expert.” Dr. Arrowsmith joined the nominating committee. The company states there are no family relationships or related-party transactions requiring disclosure for either director.
On April 22, 2026, director Matthew McMurdo resigned from the board. The company reports his resignation did not result from any disagreement regarding operations, policies, or practices.
Indaptus Therapeutics announced several board changes. The Board appointed Tim Ruan and Dr. Yi Zhang as independent Class II directors, effective April 22, 2026, with terms expiring at the 2026 annual stockholder meeting. Both bring capital markets, biotechnology, intellectual property, and life sciences expertise.
Each new director will receive an annual cash retainer of $30,000, payable quarterly, plus reimbursement of reasonable expenses, under Independent Director Agreements. They also entered Indemnification Agreements under Delaware law. Tim Ruan joins the Audit Committee and is designated an “audit committee financial expert,” while Dr. Zhang joins the Nominating Committee.
On April 22, 2026, director Matthew McMurdo resigned from the Board, and his resignation was stated not to result from any disagreement regarding operations, policies, or practices. The Board remains classified into three staggered classes, with Class II and Class III terms expiring in 2026 and 2027, respectively.
Indaptus Therapeutics, Inc. director Lu Qinglai filed an initial Form 3, which is a statement of beneficial ownership for company insiders. This filing lists no transactions and shows no reported purchases, sales, or derivative exercises by the reporting person in the data provided.
Indaptus Therapeutics, Inc. — Amendment No. 1 to a Schedule 13G/A filed by YA II PN, Ltd. states that the reporting group beneficially owns 0 shares of Common Stock, representing 0% of the class as of 12/31/2025. The filing lists affiliated entities (YA Global Investments II (U.S.), Yorkville Advisors Global, YAII GP entities, SC-Sigma, and Mark Angelo) and explains their relationships and potential attribution. The amendment is signed and dated 04/06/2026.
Indaptus Therapeutics, Inc. reported leadership and board changes. Chief Financial Officer Nir Sassi resigned effective April 1, 2026, and the company stated his resignation was not due to any disagreement regarding operations, policies, or practices.
On March 31, 2026, the board appointed Qinglai Lu, 48, as a director effective April 8, 2026 and determined he qualifies as an independent director under Nasdaq rules. The board also appointed Yu Ding, 51, as Chief Financial Officer effective April 1, 2026 after reviewing his qualifications.
The company adjusted its audit committee, with Matthew McMurdo resigning and Qinglai Lu and Jerome Jabbour joining the committee on March 31, 2026.
Indaptus Therapeutics, Inc. reported that investor Yun Yao is a more than 10% owner with 41,991,000 shares of common stock. These shares arose from a securities purchase agreement under which Yao acquired Series AA and Series AAA Convertible Non-Redeemable Preferred Stock and then converted all of it into common shares following the closing on March 23, 2026.